Frontlight ResearchEarly access
Graves' disease trials in Georgia
5 of 5 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
- Where
- Tbilisi
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- argenx
See details and how to joinNCT07570316 · EU 2025-524223-42-00 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
- Where
- Batumi, Tbilisi
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- argenx
See details and how to joinNCT07596849 · EU 2025-523333-26-00 - Phase 2Taking peopleA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Where
- Imereti, Tbilisi
- Age
- 18 years to 75 years
- People
- 210 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07018323 · EU 2025-521920-31-00 - Phase 2Enrolling by invitationA Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
- Where
- Batumi, Budapest, Kutaisi, Marneuli, Tbilisi
- Age
- 18 years and over
- People
- 372 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07286006 - Phase 2Taking peopleA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Where
- Batumi, Kutaisi, Marneuli, Tbilisi
- Age
- 18 years to 75 years
- People
- 240 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT06727604 · EU 2024-516020-33-00